Arrowhead Pharmaceuticals (ARWR)

Outperform Current rating · 2 reports

Coverage summary

Aardvark Labs Capital Research has covered Arrowhead Pharmaceuticals (ARWR) since May 8, 2026. The company is in the Healthcare sector. This page lists 2 reports: 2 earnings recaps.

The latest is the Q3 FY26 Earnings Recap, published August 5, 2026. That report moved the rating from Hold to Outperform. The rating has changed once since coverage began.

Translations: 2 in Chinese.

Rating history

May 8, 2026 First rating: Hold Q2 FY26 Earnings Recap
August 5, 2026 Hold → Outperform Q3 FY26 Earnings Recap

All ARWR reports

2026-08-05

Outperform Recap: Q3 FY26

The Left Tail Is Gone: SHASTA Delivers and the Bill for Speed Is $215 Million

2026-05-08

Hold Recap: Q2 FY26

The Beat That Wasn't: Arrowhead's Best Operating Quarter Arrives With Two Disclosures Management Left in the 10-Q